Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry
New Company, Generic Strategy, Upsher-Smith Restructuring
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.
You may also be interested in...
Chugai’s Eldecalcitol Challenge Fails In Japan
Chugai has seen its attack on Sawai and Nichi-Iko over their generic eldecalcitol rivals to the originator’s Edirol brand dismissed by a Tokyo district court.
Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality Violations
Japan struggles to recover its ever-expanding supply chain for generic drugs after several key players had their production stopped because of a series of GMP violations. As the share of generics grows under government policy, some in the industry argue the problems are deeply rooted in a decades-old pricing system.